Headline Potential Merck has three drugs currently under priority FDA review, one of them a Covid-19 drug: Molnupiravir, an antiviral for Covid-19 which has received a positive opinion from the advisory board and which Merck's CEO says should work against any variant Vaxneuvance, a pneumococcal vaccine Lynparza, a breast cancer drug Merck also...
NASDAQ:VRTX had an ongoing negative Trend since July 2020. It broke the negative Trend 2 days ago. For me its a very good chance and low price for VRTX. strong up move with good volume crossing the negative trend crossed EMA200 and MA200 on daily chart and also on weeky chart still above EMA200 and MA200 on monthly chart still in positive trend since...
Long due to multiple reasons 1. Trendline breakout 2. High volumes at breakout 3. RSI above 50 shows good relative strength 4. Pharma sector, mostly bullish at the moment 5. High risk to reward ration Disclaimer: for learning purposes only!
0.786 can be seen as a previous point of resistance now that price has moved higher than this level, it will be seen as a point of support for the breakdown of the rising wedge , a pattern that is commonly bearish (as you can see on the chart) Pharmaceutical companies are possibly hot right now, due to the emergence of the new COVID variant. Buy the Dip.
ACRX AcelRx Pharmaceuticals is a specialty pharmaceutical company that focuses on the development and commercialization of therapies for the treatment of acute pain. 52 Week Range 0.65 - 2.94 Sitting at all time low now. HC Wainwright has a 5usd price target for it. My take profits are: 1: $0.95 2: $1.23 Stop loss: $0.57
Double bottom with RSI divergence, expect 13% upside in short term Reasons: 1. double bottom 2. RSI divergence 3. Health pharma sector showing reversal signs Note: for learning purposes
TMBR Timber Pharmaceuticals had a recent public offering price of $0.64 per share of common stock and accompanying common warrant. The warrants have an exercise price of $0.70 per share. The price is now 0.47usd There is a strong upside potential short term! Price Target 1: $0.85 Price Target 2: $1.37 Stop loss: $0.41 Looking forward to read your opinion about it.
We took a short on MRNA in the high 300's or so and now Moderna is in the mid 200's. I'm looking for potential gaps to be filled on Moderna to the upside before any further move to the downside. Possiblity is still there for further downside, although this one may try to get a dead cat bounce in here. Targets : 280 340 226 LIS..
The stock has reached lower trendline and may undergo a reversal rally. Trade is supported by brokerage calls and Supports Nearby. Risk Reward Ratio - 4:1 SL is placed below support zone & the lower trendline. The target is placed near resistance.
The stock has reached lower trendline and may undergo a reversal rally. Trade is supported by brokerage calls and Supports Nearby. Risk Reward Ratio - 3:1 SL is placed below support zone & the lower trendline. The target is placed near resistance.
This one is almost pure intuition. We're in pharmaceuticals earnings season now. Seagen reports after market today. A bunch of other large holdings of XBI report on November 3-4, and a bunch more on November 8. Bonds and tech stocks have made a breakout move upward, and small caps look primed. (XBI is full of small and micro caps.) XBI has had a long consolidation...
looks like the 5 down are about finished. Would want to see an ABC correction 1st then 5 up impulsive move B4 I could make any targets.
ZNTL broke 80 again today and is displaying a strong monthly momentum chart. IBB regaining 160 hopefully will signal at least a moderate health care push that could push ZNTL into the 90s and beyond. Good luck traders!
Looks like a push to the 618 fib retracement might be up next. If we have an impulsive 5 up incoming the chart should look like this IMO.
Buy no matter what. I'm in with 40k shares, plan to buy much more for long term ( 5-10 years)
Hi there. Price is forming a big reversal pattern to change its direction. Also is close to 0 value which is a very good sign. Watch strong price action at the current levels for buy.
Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668. Merck & Co. was established as an American affiliate in 1891 Entry on the bullish break of the dynamic...